Debio-4126
- Generic Name
- Debio-4126
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 119
- Registration Number
- NCT06930625
- Locations
- 🇺🇸
Washington University-School of Medicine, Saint Louis, Missouri, United States
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Phase 1
Terminated
- Conditions
- AcromegalyGEP-NET
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 20
- Registration Number
- NCT05364944
- Locations
- 🇩🇰
Rigshospitalet, Endokrinologisk afdeling, Copenaghen, Denmark
🇫🇷AP-HP Hopital Bicetre, Le Kremlin-bicetre, France
🇫🇷AP-HM - Hôpital de la Conception, Service d'Endocrinologie et Centre de Référence des Maladies Rares de l'hypophyse, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath